Amyloid-β Monomer Clearance with Anticalins
Recent research highlights the importance of understanding the intricacies of clearing amyloid-β from the brain in treating Alzheimer’s disease. Using anticalins, a type of antigen-binding protein, scientists have found a promising approach with fewer inflammatory side-effects compared to traditional monoclonal antibodies. Targeting early forms of amyloid-β before plaque formation, the study shows positive results in an Alzheimer’s mouse model. While cautious optimism is warranted, as findings in mice do not always translate to humans, this innovative approach holds potential for future therapies.
The study sheds light on past failures in targeting amyloid-β with passive immunization and the importance of timing in therapeutic interventions. By preventing extracellular Aβ accumulation early on, researchers can potentially stop neuronal hyperactivity, a key factor in brain dysfunction. Utilizing Aβ-anticalins, which have high target affinities and low immunogenicity, this approach shows promise in suppressing hyperactivity and synaptic glutamate accumulation in early stages of the disease. These findings provide new insights into combating Alzheimer’s at its root causes.
Link: https://doi.org/10.1038/s41467-024-50153-y
